445 related articles for article (PubMed ID: 29307569)
1. Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant?
Nussinov R; Tsai CJ; Jang H
Semin Cancer Biol; 2019 Feb; 54():114-120. PubMed ID: 29307569
[TBL] [Abstract][Full Text] [Related]
2. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
Nussinov R; Zhang M; Tsai CJ; Jang H
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic Ras Isoforms Signaling Specificity at the Membrane.
Nussinov R; Tsai CJ; Jang H
Cancer Res; 2018 Feb; 78(3):593-602. PubMed ID: 29273632
[TBL] [Abstract][Full Text] [Related]
4. The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas.
Nussinov R; Muratcioglu S; Tsai CJ; Jang H; Gursoy A; Keskin O
Mol Cancer Res; 2015 Sep; 13(9):1265-73. PubMed ID: 26085527
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic KRas mobility in the membrane and signaling response.
Nussinov R; Tsai CJ; Jang H
Semin Cancer Biol; 2019 Feb; 54():109-113. PubMed ID: 29499269
[TBL] [Abstract][Full Text] [Related]
6. The Mystery of Rap1 Suppression of Oncogenic Ras.
Nussinov R; Jang H; Zhang M; Tsai CJ; Sablina AA
Trends Cancer; 2020 May; 6(5):369-379. PubMed ID: 32249186
[TBL] [Abstract][Full Text] [Related]
7. K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?
Nussinov R; Muratcioglu S; Tsai CJ; Jang H; Gursoy A; Keskin O
Expert Opin Ther Targets; 2016 Jul; 20(7):831-42. PubMed ID: 26873344
[TBL] [Abstract][Full Text] [Related]
8. Targeting the α4-α5 interface of RAS results in multiple levels of inhibition.
Spencer-Smith R; Li L; Prasad S; Koide A; Koide S; O'Bryan JP
Small GTPases; 2019 Sep; 10(5):378-387. PubMed ID: 28692342
[TBL] [Abstract][Full Text] [Related]
9. Comparison of liver oncogenic potential among human RAS isoforms.
Chung SI; Moon H; Ju HL; Kim DY; Cho KJ; Ribback S; Dombrowski F; Calvisi DF; Ro SW
Oncotarget; 2016 Feb; 7(6):7354-66. PubMed ID: 26799184
[TBL] [Abstract][Full Text] [Related]
10. Flexible-body motions of calmodulin and the farnesylated hypervariable region yield a high-affinity interaction enabling K-Ras4B membrane extraction.
Jang H; Banerjee A; Chavan T; Gaponenko V; Nussinov R
J Biol Chem; 2017 Jul; 292(30):12544-12559. PubMed ID: 28623230
[TBL] [Abstract][Full Text] [Related]
11. Calmodulin and PI3K Signaling in
Nussinov R; Wang G; Tsai CJ; Jang H; Lu S; Banerjee A; Zhang J; Gaponenko V
Trends Cancer; 2017 Mar; 3(3):214-224. PubMed ID: 28462395
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
[TBL] [Abstract][Full Text] [Related]
13. Distinct Binding Preferences between Ras and Raf Family Members and the Impact on Oncogenic Ras Signaling.
Terrell EM; Durrant DE; Ritt DA; Sealover NE; Sheffels E; Spencer-Smith R; Esposito D; Zhou Y; Hancock JF; Kortum RL; Morrison DK
Mol Cell; 2019 Dec; 76(6):872-884.e5. PubMed ID: 31606273
[TBL] [Abstract][Full Text] [Related]
14. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
Huang L; Counter CM
PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
[TBL] [Abstract][Full Text] [Related]
15. Reconstitution and characterization of BRAF in complex with 14-3-3 and KRAS4B on nanodiscs.
Liu NF; Enomoto M; Marshall CB; Ikura M
Protein Sci; 2024 Jun; 33(6):e5016. PubMed ID: 38747381
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic K-Ras4B Dimerization Enhances Downstream Mitogen-activated Protein Kinase Signaling.
Muratcioglu S; Aydin C; Odabasi E; Ozdemir ES; Firat-Karalar EN; Jang H; Tsai CJ; Nussinov R; Kavakli IH; Gursoy A; Keskin O
J Mol Biol; 2020 Feb; 432(4):1199-1215. PubMed ID: 31931009
[TBL] [Abstract][Full Text] [Related]
17. Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling.
Villalonga P; López-Alcalá C; Bosch M; Chiloeches A; Rocamora N; Gil J; Marais R; Marshall CJ; Bachs O; Agell N
Mol Cell Biol; 2001 Nov; 21(21):7345-54. PubMed ID: 11585916
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic Screening Identifies Protein Synthesis Inhibitors as H-Ras-Nanocluster-Increasing Tumor Growth Inducers.
Najumudeen AK; Posada IM; Lectez B; Zhou Y; Landor SK; Fallarero A; Vuorela P; Hancock J; Abankwa D
Biochemistry; 2015 Dec; 54(49):7212-21. PubMed ID: 26568031
[TBL] [Abstract][Full Text] [Related]
19. ASPP2 Is a Novel Pan-Ras Nanocluster Scaffold.
Posada IM; Serulla M; Zhou Y; Oetken-Lindholm C; Abankwa D; Lectez B
PLoS One; 2016; 11(7):e0159677. PubMed ID: 27437940
[TBL] [Abstract][Full Text] [Related]
20. Intrinsic protein disorder in oncogenic KRAS signaling.
Nussinov R; Jang H; Tsai CJ; Liao TJ; Li S; Fushman D; Zhang J
Cell Mol Life Sci; 2017 Sep; 74(17):3245-3261. PubMed ID: 28597297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]